Eye Health News and Research

Latest Eye Health News and Research

AGN-209323 small molecule for neuropathic pain: Bristol-Myers Squibb, Allergan announce global agreement

Bristol-Myers Squibb Company and Allergan, Inc. today announced a global agreement for the development and commercialization of AGN-209323, a Phase II-ready, orally administered small molecule in clinical development for neuropathic pain.

3 Mar 2010

Allergan celebrates 20th anniversary of BOTOX in Canada

Twenty years ago, the first approved use of BOTOX(R) (botulinum toxin type A), a neurotoxin widely used to treat several life altering medical conditions, was granted in Canada. As part of the 20th anniversary celebrations, healthcare professionals from coast to coast reflect upon the discovery, science and evolution of a therapy that has impacted the lives of millions of patients worldwide.

3 Mar 2010

Eye injuries in young children: Keep liquid detergent capsules out of reach

In this week's BMJ, senior eye doctors are warning people to keep liquid capsules for fabric detergents out of the reach of children after a wave of eye injuries in young children at their hospital.

3 Mar 2010

Merck’s MF/F Phase III study data presented at AAAAI annual meeting

Data from two Phase III studies of Merck’s investigational fixed-dose combinations of mometasone furoate and formoterol fumarate (MF/F) were presented by researchers today in two poster presentations at the American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting.

3 Mar 2010

Harvard Professor urges medical community to use ultrasound for diagnosing acute female pelvic conditions

In a bold, eye-opening editorial in the March 2010 issue of the Journal of Ultrasound in Medicine, Harvard Professor, Beryl Benacerraf, MD, urges the medical community to use ultrasound instead of Computed Tomography (CT) as the first-line imaging test for better diagnosis capability in the evaluation of acute female pelvic and lower abdominal conditions.

3 Mar 2010

China's SFDA approves Sunridge International's PNT treatment for glaucoma and ocular hypertension

Sunridge International, announced today that China's State Food and Drug Administration, (SFDA), had approved the firm's Pneumatic Trabeculoplasty (PNT) treatment in China.

3 Mar 2010

Phase III study results of Merck's allergy immunotherapy tablet

In new data from a Phase III study in 345 children and adolescents (ages 5-17 years), patients with grass pollen allergic rhinoconjunctivitis treated with Merck's investigational sublingual grass (Phleum Pratense) allergy immunotherapy tablet (AIT) showed a 26 percent greater improvement in the total combined score (daily symptom score and daily medication score), compared to patients receiving placebo

3 Mar 2010

EMA accepts the filing of Lux Biosciences' MAA for Luveniq

Lux Biosciences, Inc. today announced that the European Medicines Agency has accepted the filing of the company’s Marketing Authorization Application (MAA) for the company’s lead product, Luveniq™ (LX211; oral voclosporin) for the treatment of noninfectious uveitis involving the intermediate or posterior segments of the eye.

3 Mar 2010

Advanced Cell Technology’s MA09-hRPE cells for treatment of SMD: FDA grants orphan drug designation

Advanced Cell Technology, Inc., a biotechnology company applying cellular technology in the field of regenerative medicine, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the company’s MA09-hRPE cells for use in the treatment of Stargardt’s Macular Dystrophy (SMD). As a result, the company is eligible to receive a number of benefits, including tax credits, access to grant funding for clinical trials, accelerated FDA approval and allowance for marketing exclusivity after drug approval for a period of as long as seven years.

3 Mar 2010

EMA validates Lux Biosciences' voclosporin MAA

Isotechnika Pharma Inc. today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) filed by its partner, Lux Biosciences, Inc., for voclosporin. Following validation of the MAA, the dossier is distributed to members of the Committee for Medicinal Products for Human Use (CHMP) for formal review, which is expected to take one year.

2 Mar 2010

Corneal transplant surgery: DSAEK leads to greater cell loss overall than PKP

One year post-surgery, patients who underwent Descemet's stripping automated endothelial keratoplasty (DSAEK) experienced greater cell loss overall compared to those who underwent penetrating keratoplasty (PKP), according to a new analysis of data collected from the Cornea Donor Study (CDS) Investigator Group's 2008 Specular Microscopy Ancillary Study (SMAS). However, the study, published in the March issue of Ophthalmology, showed that cell loss in DSAEK patients plateaued more quickly than in those who underwent PKP.

2 Mar 2010

Visually impaired children benefit from earlier introduction to long cane

When "T" started kindergarten, she was an independent, confident child who was fully able to move about in her new environment—even though she was the only visually impaired child in her school and used a long cane. T was born in 2003 with Leber's congenital amaurosis, a rare inherited eye disease, and has no light perception. She was introduced to the long cane at the early age of 14 months to foster her independence of mobility and functioning.

2 Mar 2010

Researchers develop sensitive measuring system for cGVHD

Researchers from The University of Texas M. D. Anderson Cancer Center have developed a new assessment tool to measure the severity of symptoms that can complicate stem cell transplantation. The tool assesses symptoms resulting from chronic graft-versus-host disease (cGVHD), and was presented with supporting research at the 2010 Bone and Marrow Transplant Tandem Meeting.

2 Mar 2010

Quark Pharmaceuticals commences dosing in clinical study of QPI-1007 for NAION

Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, announced today the dosing of the first patient in a Phase I study of the investigational neuroprotective agent, QPI-1007.

2 Mar 2010

Regular use of aspirin, acetaminophen and NSAIDs increases risk of hearing loss in men

In a study published in the March 2010 issue of The American Journal of Medicine, researchers determined that regular use of aspirin, acetaminophen and non-steroidal anti-inflammatory drugs (NSAIDs) increases the risk of hearing loss in men, particularly in younger men, below age 60.

1 Mar 2010

Article describing novel biological properties of Thymosin beta 4 peptide fragments published

REGENERX BIOPHARMACEUTICALS, INC. announced today that a university research team has published an article ahead of print in FASEB Journal, a high-impact scientific journal, describing novel biological properties of several Thymosin beta 4 (Tβ4) peptide fragments.

27 Feb 2010

University of Michigan Health System opens new facility for eye care, diabetes research

On March 1, the first eye patients will enter an innovative new $132 million facility that expands the University of Michigan Health System's capacity for eye care, research and education, and unites diabetes researchers as they work to accelerate the search for a cure and prevention of diabetes.

27 Feb 2010

ONA: Cutting 300,000 hours of RN care per year may affect quality of patient care

Ontario Nurses' Association President Linda Haslam-Stroud, RN is expressing deep concerns about the quality of patient care at The Ottawa Hospital following word that the facility is cutting approximately 300,000 hours of RN care per year.

27 Feb 2010

Unilens Vision's royalty income for FY2010 second-quarter increases 12.7%

Unilens Vision Inc., which develops, licenses, manufactures, distributes and markets specialty contact lenses, today reported its operating results for the second quarter ended December 31, 2009 (FY2010).

26 Feb 2010

Notch-blocking drug effective against brain cancer stem cells, but more than one targeted attack needed

Working with mice, Johns Hopkins scientists who tested drugs intended to halt growth of brain cancer stem cells - a small population of cells within tumors that perpetuate cancer growth - conclude that blocking these cells may be somewhat effective, but more than one targeted drug attack may be needed to get the job done.

26 Feb 2010

Eye Health News and Research

Latest Eye Health News and Research

AGN-209323 small molecule for neuropathic pain: Bristol-Myers Squibb, Allergan announce global agreement

Allergan celebrates 20th anniversary of BOTOX in Canada

Eye injuries in young children: Keep liquid detergent capsules out of reach

Merck’s MF/F Phase III study data presented at AAAAI annual meeting

Harvard Professor urges medical community to use ultrasound for diagnosing acute female pelvic conditions

China's SFDA approves Sunridge International's PNT treatment for glaucoma and ocular hypertension

Phase III study results of Merck's allergy immunotherapy tablet

EMA accepts the filing of Lux Biosciences' MAA for Luveniq

Advanced Cell Technology’s MA09-hRPE cells for treatment of SMD: FDA grants orphan drug designation

EMA validates Lux Biosciences' voclosporin MAA

Corneal transplant surgery: DSAEK leads to greater cell loss overall than PKP

Visually impaired children benefit from earlier introduction to long cane

Researchers develop sensitive measuring system for cGVHD

Quark Pharmaceuticals commences dosing in clinical study of QPI-1007 for NAION

Regular use of aspirin, acetaminophen and NSAIDs increases risk of hearing loss in men

Article describing novel biological properties of Thymosin beta 4 peptide fragments published

University of Michigan Health System opens new facility for eye care, diabetes research

ONA: Cutting 300,000 hours of RN care per year may affect quality of patient care

Unilens Vision's royalty income for FY2010 second-quarter increases 12.7%

Notch-blocking drug effective against brain cancer stem cells, but more than one targeted attack needed

Genetics & Genomics - Second Edition eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Eye Health News and Research

Latest Eye Health News and Research

Genetics & Genomics - Second Edition eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Newsletters you may be interested in